Anaemia in diabetes: is there a rationale to TREAT?
- First Online:
- Cite this article as:
- Thomas, M.C., Cooper, M.E., Rossing, K. et al. Diabetologia (2006) 49: 1151. doi:10.1007/s00125-006-0215-6
- 543 Downloads
Anaemia is a common finding in patients with diabetes, particularly in those with overt nephropathy or renal impairment. In tertiary clinics, at least one outpatient in five with diabetes has anaemia, for whom it constitutes a significant additional burden.
Anaemia is associated with an increased risk of diabetic complications including nephropathy, retinopathy and macrovascular disease. Anaemia may also be significant in determining the outcome of heart failure and hypoxia-induced organ damage in diabetes. While several factors contribute to the increased prevalence of anaemia in diabetes, the failure of the kidney to increase erythropoietin in response to falling haemoglobin appears to be the dominant factor. Although there is a clear rationale for correcting anaemia in people with diabetes, it remains to be established whether this will lead to improved outcomes. Moreover, the balance of risks, costs, and benefits remains to be established in patients with diabetes. The Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alpha) Therapy (TREAT) is a randomised controlled trial designed to determine the impact of anaemia correction on mortality and non-fatal cardiovascular events in patients with type 2 diabetes and stage 3–4 nephropathy.
It is anticipated that TREAT will help to define the optimal approach to the management of anaemia in diabetes.
KeywordsAnaemiaDiabetesDiabetic nephropathyHaemoglobinMicrovascular disease
chronic kidney disease
end stage renal disease
Trial to Reduce Cardiovascular Events with Aranesp Therapy
Anaemia is a common finding in chronic kidney disease (CKD), affecting over half of all patients . Diabetes, as the most common single cause of CKD in the Western world, is therefore also the most common cause of renal anaemia. However, anaemia is also more common in diabetic nephropathy than in other renal diseases. For example, the Third National Health and Nutrition Examination Survey found that people in the general population with diabetes were nearly twice as likely to have anaemia as people without diabetes but with a similar degree of renal impairment . Anaemia also develops earlier and is more severe in patients with diabetes than in patients with renal impairment from other causes [3, 4].
Anaemia can adversely affect the health of patients with diabetes. It may have a major impact on their sense of well-being, as well as impairing their ability to work and affecting their social and sexual lives. Anaemia is known to contribute significantly to morbidity, causing symptoms such as lack of energy, breathlessness, dizziness, poor appetite, reduced cognitive function and reduced exercise tolerance [5, 6]. For patients with diabetes, many of whom already have an impaired quality of life, anaemia constitutes an unwelcome additional burden. A reduced haemoglobin (Hb) level also identifies patients with diabetes at increased risk of adverse outcomes, independent of the presence or severity of nephropathy [7, 8]. In addition, anaemia itself may contribute to the development and progression of micro- and macrovascular complications of diabetes.
Despite these facts, anaemia is unrecognised and largely untreated in patients with diabetes. This review will examine the factors leading to anaemia and its potential consequences in diabetes. In addition, we will explore the potential utility for anaemia correction.
How common is anaemia in diabetes?
Which patients will have anaemia?
An increased prevalence of anaemia is also seen in diabetic patients without renal impairment (GFR>90 ml min−1 1.73 m−2) [9–11]. However, this does not mean that these patients do not have diabetic renal disease. Anaemia is also independently associated with albuminuria (Fig. 2), an early marker of microvascular inflammation and damage , which, like anaemia , precedes declining renal function associated with late-stage nephropathy. Recently, it has also been shown that, even in the absence of albuminuria, anaemia in patients with diabetes is largely the result of impaired renal functioning . These strong links between the kidney and anaemia in diabetes probably reflect the unique vulnerability of the renal microcirculation to damage in diabetes . Moreover, it is likely that significant damage is present before albumin is found in the urine . Nonetheless, in a tertiary clinic setting, most patients with diabetes and anaemia can be identified by examining patients with moderate to severe renal impairment (GFR<60 ml min−1 1.73 m−2) and/or elevated albuminuria (>20 μg/min).
The role of erythropoietin deficiency in diabetes-associated anaemia
Possible factors contributing to anaemia in patients with diabetes
Reduced renal production of erythropoietin
Reduced red cell survival
Reduced iron availability
Occult blood loss
Increased salt reabsorption
Coeliac disease (type 1 diabetes)
Drug therapy (e.g. renin–angiotensin system blockade, thiazolidinediones)
Urinary erythropoietin loss
While these findings confirm the failure of the kidney to produce erythropoietin in response to falling Hb as a key component of anaemia in patients with diabetes, that is not to say that other (non-renal) factors do not contribute. On the contrary, patients with diabetes have several metabolic and functional abnormalities of their red blood cells, including reduced erythrocyte survival . Diabetes is also associated with systemic inflammation, occult blood loss and haematinic deficiencies . Indeed, one-third of patients with functional erythropoietin deficiency in our surveys also have reduced iron availability. Thus, in the setting of impaired renal compensation, it is conceivable that even minor changes in red cell turnover or iron availability may contribute to a progressive fall in Hb and ultimately anaemia. As a result, the standard thresholds used to denote absolute iron deficiency may be inappropriately low for patients with diabetic kidney disease. The same phenomenon can be observed in patients on haemodialysis, who may still be responsive to iron supplementation despite relatively normal iron indices (functional iron deficiency).
Why does the diabetic kidney not generate adequate erythropoietin in response to anaemia?
The precise mechanisms by which diabetes impairs the renal erythropoietin response to reduced Hb remain to be established. While functional erythropoietin deficiency is clearly linked to renal dysfunction in diabetes, the reduction in synthesis of erythropoietin in response to anaemia appears to be beyond that seen in other renal (and particularly glomerular) diseases . A number of mechanisms potentially contribute to the preferential development of anaemia in patients with diabetes. For example, the predominance of damage to specific cells and to the vascular architecture of the renal tubulointerstitium, and the resulting systemic inflammation, autonomic neuropathy, and induction of inhibitors of erythropoietin release, have all been suggested as contributors to impaired renal erythropoietin production and release.
Like anaemia, tubulointerstitial damage can be seen in diabetes, independent of and in advance of later changes, such as declining GFR. For example, thickening and reduplication of the tubular and epithelial basement membrane can be readily observed in the early diabetic kidney, even among normoalbuminuric patients . It is conceivable that damage to the erythropoietin-producing cells in the cortical interstitium or disruption of the delicate interaction between tubule, peritubular fibroblast and endothelium that is required for normal haematopoietic function in the kidney may contribute to impaired erythropoietin release. In fact, endogenous erythropoietin production has been suggested as a possible marker of the severity of tubulointerstitial damage in diabetes . However, the fact that patients with diabetes and anaemia are able to mount an appropriate response to acute hypoxia , suggests that the cells which produce erythropoietin are not simply lost in diabetes. Rather that the ‘tissue oxygenation-erythropoietin—Hb’ feedback mechanism may operate at a lower set-point in the diabetic tubule and peritubular milieu.
Does anaemia contribute to diabetic complications?
Anaemia may contribute to both morbidity and mortality in diabetes in a number of ways. Certainly, untreated anaemia significantly contributes to the reduced quality of life seen in patients with CKD, including impaired physical performance, cognitive function, sleep, appetite, sexual function, social activities, and employment. For example, in a recent survey, over half of all patients with diabetes experienced tiredness to some extent and this proportion increased to 74% in those with anaemia . Furthermore, fatigue was associated with significant functional morbidity, reduced independence and a poorer quality of life.
Anaemia is associated with an increased risk of the vascular complications of diabetes including nephropathy [7, 25, 26], retinopathy [27, 28], neuropathy , impaired wound healing  and macrovascular disease. A reduced Hb, even within the normal range, identifies patients with type 2 diabetes who are at increased risk of progressive renal disease, hospitalisation and premature death . It is important to note that anaemia per se does not cause microvascular injury (e.g. chronic iron deficiency does not lead to end-stage renal disease [ESRD]). Moreover, because anaemia may be considered a manifestation of microvascular disease , it is easy to understand why patients with anaemia, as a surrogate marker for co-morbidity, may appear more prone to microvascular complications. However, there is some evidence to suggest that anaemia may also modulate the activity of pathways that lead to progressive end-organ damage in diabetes.
Tissue hypoxia is known to have a key role in diabetes-associated organ damage, associated with a range of mitogenic and fibrogenic effects implicated in the progression of microvascular disease. For example, hypoxia modifies the expression of genes involved in angiogenesis and capillary permeability, vasomotor response, glycolysis, matrix metabolism and cell survival . Anaemia may also have important haemodynamic effects in diabetic tissues. For example, anaemia independently results in elevated sympathetic activity, activation of the intra-renal renin–angiotensin system and release of antidiuretic hormone , all pathways that are implicated in the development of proteinuria  and hypertension in CKD .
In the heart, chronic anaemia results in increased cardiac output, volume overload, increased heart rate and, ultimately, progressive left ventricular hypertrophy and diastolic dysfunction. In addition, an increase in myocardial hypoxia associated with anaemia may be particularly important in patients with diabetes, because many also have established cardiovascular disease or impaired cardiac function. In particular, the kind of diabetic patients that will have anaemia (those with overt nephropathy, renal impairment, prolonged duration of disease. etc.) are precisely the patients that have cardiac disease. For example, we have recently shown that 94% of unselected diabetic patients with anaemia have abnormal cardiac function that is detectable on transthoracic echocardiography, associated with increased left ventricular mass and impaired relaxation indices . It is now clear that anaemia is a potent adverse risk factor for new-onset heart failure , as well as a marker for poor outcomes in patients with established cardiac dysfunction . Anaemia may be operating in the same way in patients with diabetes (given that most diabetic patients with anaemia have cardiac dysfunction). Moreover, the increased prevalence of anaemia in patients with diabetes may contribute to the worse prognosis of heart failure in patients with diabetes compared to non-diabetic patients .
What evidence is there for correcting anaemia?
At present, there is no conclusive evidence that correcting anaemia significantly improves clinical outcomes in patients with CKD, apart from quality-of-life indices . Nonetheless, from the perspective of a patient with diabetic nephropathy (and therefore risk of heart failure, CHD, retinopathy, etc.), an intervention that reproducibly improves ability to work, exercise tolerance, and cognitive and sexual function is not insignificant. Consequently, current international guidelines allow the use of erythropoietin in patients with CKD and anaemia when other causes have been excluded . However, many countries limit the use of erythropoietin to patients with severe renal impairment or ESRD. Such a practice is clearly problematic because the likelihood of functional erythropoietin deficiency as a contributor to anaemia in patients with diabetes is not dependent on the severity of renal impairment. In addition, most patients with diabetes do not survive long enough to develop severe renal impairment nor to develop anaemia severe enough to qualify for therapy under the current guidelines. Furthermore, some data suggest that early correction of anaemia may be more beneficial than late interventions, where complications are advanced and irreversible. For example, while correction of anaemia in patients with advanced kidney disease may stabilise left ventricular hypertrophy , earlier intervention may lead to regression .
There is limited evidence to suggest that correction of anaemia, specifically in patients with complications of diabetes, might be beneficial. For example, a few small studies have demonstrated that correction of anaemia is associated with a reduction in retinal exudates  and macular oedema . Treatment with erythropoietin in diabetic patients with heart failure may also reduce the length of hospitalisation and improve New York Heart Association functional class . In experimental models of diabetes, treatment with erythropoietin has been shown to protect against the development of diabetic neuropathy as well as to reverse established disease . However, it remains to be established whether these actions are the result of correction of the anaemia, or of the pleiotropic actions of erythropoietin on the physiological response to hypoxia and oxidative stress .
A rationale to TREAT
Given that anaemia associated with functional erythropoietin deficiency is common in patients with diabetes, there is a clear rationale for the use of erythropoietin or related analogues in diabetic patients. However, while correction of anaemia improves quality of life and exercise tolerance, the impact of anaemia correction on hard clinical outcomes in patients with diabetes remains to be established. Moreover, there is a clear potential for deleterious effects from erythropoietin, such as raised blood pressure, increased blood viscosity and elevated peripheral vascular resistance, which may have negative impacts on patients with diabetes. Erythropoietin is also a potentially costly addition to an already stretched pharmaceutical budget. Consequently, the true balance of risks and benefits can only be answered by large randomised controlled studies.
TREAT is an international, multicentre, double-blind randomised controlled trial designed to test the hypothesis that correction of anaemia (as defined by Hb≤110 g/l) with the erythropoietin analogue, darbepoetin alpha, to a target Hb of 130 g/l in patients with CKD and type 2 diabetes mellitus will reduce the risk of a composite primary end point of death or cardiovascular morbidity, including myocardial infarction, acute myocardial ischaemia, congestive heart failure, and stroke. Eligible TREAT subjects should have type 2 diabetes mellitus and CKD, defined by an estimated GFR of 20–60 ml min−1 1.73 m−2. Consequently, most patients will have moderate renal impairment, rather than the severe or pre-ESRD studied in previous and current trials (e.g. CREATE , CHOIR ). As most patients with diabetic nephropathy do not survive long enough to develop ESRD, targeted intervention in these patients would seem to be more logical than delayed intervention in selected survivors with advanced disease.
TREAT is an event-driven trial and is currently enrolling approximately 4,000 eligible subjects over 2 years. It is expected that the majority of subjects will be recruited in North America, Western Europe, Australia and Latin America. This sample size should yield approximately 1,203 composite primary events over a total of approximately 4.5 years of study, providing 80% power to detect a treatment effect of 20%. Enrolled subjects will be randomised either to receive darbepoetin alpha to achieve and maintain target Hb of 130 g/l or to the control arm, where they will receive placebo for Hb≥90 g/l and rescue therapy with darbepoetin alpha for Hb<90 g/l until Hb is again ≥90 g/l, when placebo will resume.
Justification for the threshold Hb level for rescue of 90 g/l is based on clinical and statistical considerations. First, it is designed to protect patient safety by minimising symptomatic anaemia. The guidelines of the National Kidney Foundation for anaemia management in CKD indicate that quality of life is either not influenced or is influenced only slightly when Hb increases from 80 to 90–100 g/l, and reviews of clinical trials by the Cochrane Collaboration indicate that there is no increased safety risk at an Hb of 90 g/l as compared with higher Hb . Moreover, there are currently no convincing trial data to support the correction of anaemia in these patients. Consistent with previous studies in CKD , it is expected that less than 10% of subjects in the placebo arm will experience an Hb<90 g/l and therefore require rescue therapy with darbepoetin alpha. Lastly, statistical modelling suggests a feasible sample size with the threshold for Hb rescue set at 90 g/l.
In summary, anaemia is a common finding in diabetes, particularly in patients with overt nephropathy or renal impairment. In tertiary clinics at least one outpatient in five with type 1 or type 2 diabetes has anaemia [10, 11], to whom it constitutes a significant additional burden. Anaemia is associated with an increased risk of diabetic complications including nephropathy, retinopathy and neuropathy. Anaemia may also be significant in determining the outcome of heart failure and hypoxia-induced organ damage associated with macrovascular disease in diabetes. Although there is a clear rationale to correct functional erythropoietin deficiency in patients with diabetes, there is currently no trial evidence for this practice. Moreover, the balance of risks, costs and benefits remains to be established in patients with diabetes. TREAT is designed to provide the critical and unbiased risk/benefit information that is needed to guide medical practice in this high-risk population, and will help define the optimal approach to the management of anaemia in diabetes. In the meantime, the detection of anaemia should be used to identify patients with diabetes who are at increased risk of adverse clinical outcomes. Optimal metabolic and blood pressure control remain the best way to prevent anaemia by preventing microvascular damage at the outset.